Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PAHC
PAHC logo

PAHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
39.850
Open
39.430
VWAP
37.08
Vol
991.42K
Mkt Cap
1.47B
Low
35.080
Amount
36.77M
EV/EBITDA(TTM)
9.36
Total Shares
40.56M
EV
2.28B
EV/OCF(TTM)
34.49
P/S(TTM)
1.09
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
Show More

Events Timeline

(ET)
2026-05-06
16:50:00
Raises FY26 Revenue Outlook to $1.46B-$1.5B
select
2026-05-06
16:40:00
Phibro Animal Health Reports Q3 Revenue of $383.5M
select
2026-04-27 (ET)
2026-04-27
16:40:00
Phibro Animal Health Announces New Regulatory Framework in Brazil
select
2026-02-04 (ET)
2026-02-04
16:30:00
Raises FY26 Revenue Outlook to $1.45B
select
2026-02-04
16:30:00
Company Reports Q2 Revenue of $373.9M, Exceeding Expectations
select
2025-12-18 (ET)
2025-12-18
16:20:00
Phibro Animal Health Corporation Leadership Transition Supports Long-Term Growth
select

News

seekingalpha
9.5
05-08seekingalpha
Phibro Animal Health Corporation Q3 2026 Earnings Highlights
  • Significant Sales Growth: Phibro Animal Health Corporation reported net sales of $383 million in Q3, a 10% increase, indicating strong ongoing demand in the animal health sector, which is expected to further drive revenue growth in the future.
  • Steady EBITDA Improvement: Adjusted EBITDA rose 11% to $60 million, reflecting the company's success in cost control and operational efficiency, thereby enhancing its financial stability and investment appeal.
  • Launch of Sustainable Solutions Platform: The introduction of the new sustainability solutions platform, Verratain, aims to assist companies in achieving their environmental goals, potentially opening up multi-billion dollar market opportunities and enhancing competitive positioning.
  • Enhanced Credit Flexibility: Phibro increased its revolving credit facility by $125 million through an oversubscribed process, further bolstering the company's financial flexibility and providing stronger support for future investments and expansions.
Newsfilter
1.0
05-07Newsfilter
Phibro Animal Health to Attend Healthcare Conference
  • Conference Participation: Phibro Animal Health Corporation will participate in the Bank of America Securities Healthcare Conference on May 13, 2026, where executives will present the company's strategic and financial outlook to analysts and investors.
  • Executive Lineup: The event will feature Executive Vice President and CEO Designate Daniel Bendheim, COO Larry Miller, and CFO Glenn David, showcasing the leadership team and strategic direction of the company.
  • Live and Replay Access: The live audio presentation will be available on Phibro's Investor Relations website, ensuring that investors can access real-time information, while a replay will also be archived for later viewing, enhancing transparency and communication with stakeholders.
  • Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, underscoring its significant role in the industry.
seekingalpha
9.5
05-06seekingalpha
Phibro Animal Q3 Earnings Beat Expectations
  • Strong Earnings Performance: Phibro Animal Health reported a Q3 Non-GAAP EPS of $0.76, beating expectations by $0.05, indicating a sustained improvement in profitability that boosts investor confidence.
  • Significant Revenue Growth: The company achieved Q3 revenue of $383.5 million, a 5.4% year-over-year increase, surpassing expectations by $16.48 million, demonstrating effective execution of sales strategies and solidifying its market position.
  • Updated Future Guidance: Phibro updated its fiscal year 2026 guidance, projecting net sales between $1.46 billion and $1.50 billion, with adjusted EBITDA expected to be between $247 million and $255 million, reflecting management's confidence in future growth and strategic planning.
  • Stock Price Volatility: Despite strong earnings, Phibro Animal's shares fell by 12.5%, potentially indicating market concerns about the broader economic environment, prompting investors to monitor subsequent market reactions.
Fool
5.0
04-28Fool
Phibro Animal Health CEO Executes Significant Stock Sale
  • Executive Stock Sale: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 21,120 shares of common stock through BFI Co. LLC between April 21 and April 23, 2026, totaling approximately $1.2 million, indicating a strategic management of liquidity.
  • Ownership Changes: This transaction reduced Bendheim's indirect holdings by 15.78%, leaving him with 95,880 indirect shares while maintaining 16,840 direct shares, suggesting continued confidence in the company's prospects.
  • Strong Financial Performance: Phibro reported a 21% year-over-year increase in second-quarter sales to $373.9 million, with net income soaring from $3.2 million to $27.5 million, highlighting robust growth in the animal health sector.
  • Optimistic Future Outlook: The company anticipates a 14% increase in sales for fiscal 2026, with net income projected to rise by 86% within management's guidance range, reflecting its competitive edge and ongoing business expansion potential.
Newsfilter
7.0
04-27Newsfilter
Phibro Animal Health Implements New Regulatory Framework in Brazil
  • Regulatory Implementation: Phibro Animal Health Corporation announced the implementation of a new regulatory framework in Brazil that prohibits the importation, manufacture, and sale of antimicrobial-containing feed additives, effective April 27, 2026, with a 180-day transition period to align with global regulatory standards.
  • Transition Period: During the 180-day transition, companies and customers can continue using products under existing labels, which is expected to minimize the regulatory change's impact on Phibro's fiscal year 2026 results, ensuring a smoother adjustment process.
  • Veterinary Prescription Requirement: Following the transition, the use of the specified antimicrobials will require a veterinary prescription, and Phibro is introducing the PhibroVet® digital platform to facilitate the creation and management of prescriptions, enhancing compliance and operational efficiency.
  • Registration Progress: Phibro is actively collaborating with Brazil's Ministry of Agriculture and Livestock (MAPA) on the registration of virginiamycin for therapeutic use, which is anticipated to be approved during the transition period, further solidifying its market position in Brazil.
NASDAQ.COM
7.5
03-24NASDAQ.COM
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
  • Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
  • Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
  • Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
  • Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
Wall Street analysts forecast PAHC stock price to rise
2 Analyst Rating
Wall Street analysts forecast PAHC stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
45.00
Averages
47.50
High
50.00
Current: 0.000
sliders
Low
45.00
Averages
47.50
High
50.00
Citi
Neutral
initiated
$62
AI Analysis
2026-04-15
Reason
Citi
Price Target
$62
AI Analysis
2026-04-15
initiated
Neutral
Reason
Citi initiated coverage of Phibro Animal Health with a Neutral rating and $62 price target. The firm launched the animal health and dental sectors with a "cautiously optimistic" view. Citi favors the animal health group, saying the the "humanization" pet trend is real and should drive more spending. The firm's top pick is Zoetis. It sees the weak macro backdrop pressuring the dental sector. Citi expects a trade-down to lower cost implants and orthodontics. Citi's top dental pick is Henry Schein.
Morgan Stanley
Equal Weight
maintain
$45 -> $49
2026-02-06
Reason
Morgan Stanley
Price Target
$45 -> $49
2026-02-06
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Phibro Animal Health to $49 from $45 and keeps an Equal Weight rating on the shares. Phibro's latest print reflects solid execution, particularly around its Zoetis MFA transaction/Animal Health segment/cost management, with a Q2 beat, raised FY26 guidance, and notable margin expansion, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PAHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Phibro Animal Health Corp (PAHC.O) is 13.83, compared to its 5-year average forward P/E of 13.07. For a more detailed relative valuation and DCF analysis to assess Phibro Animal Health Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.07
Current PE
13.83
Overvalued PE
16.03
Undervalued PE
10.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.08
Current EV/EBITDA
9.62
Overvalued EV/EBITDA
10.66
Undervalued EV/EBITDA
7.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.79
Current PS
1.05
Overvalued PS
1.05
Undervalued PS
0.52

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Price prediction PM
Intellectia · 530 candidates
One Day Rise Prob: >= 70One Day Predict Return: >= 0.0%One Week Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
MGLD logo
MGLD
Marygold Companies Inc
49.97M
YB logo
YB
Yuanbao Inc
754.79M
UROY logo
UROY
Uranium Royalty Corp
556.63M
CANG logo
CANG
Cango Inc
191.12M
SCII logo
SCII
SC II Acquisition Corp
248.98M
JBS logo
JBS
Jbs NV
17.22B
Stocks for short term gans
Intellectia · 19 candidates
Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
LBTYB logo
LBTYB
Liberty Global Ltd
6.07B
PAHC logo
PAHC
Phibro Animal Health Corp
2.15B
ALGT logo
ALGT
Allegiant Travel Co
2.10B
NVST logo
NVST
Envista Holdings Corp
4.77B
XPO logo
XPO
XPO Inc
23.85B
RRX logo
RRX
Regal Rexnord Corp
14.06B
what stocks will
Intellectia · 3459 candidates
Market Cap: >= 100.00MPrice: $1.00 - $200.00Monthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
KELYB logo
KELYB
Kelly Services Inc
510.65M
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
PAHC logo
PAHC
Phibro Animal Health Corp
1.66B
FORM logo
FORM
FormFactor Inc
5.43B
LBRX logo
LBRX
LB Pharmaceuticals Inc
526.22M
ENSG logo
ENSG
Ensign Group Inc
10.05B

Whales Holding PAHC

C
Castleknight Management LP
Holding
PAHC
+38.36%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Phibro Animal Health Corp (PAHC) stock price today?

The current price of PAHC is 36.32 USD — it has decreased -9.2

What is Phibro Animal Health Corp (PAHC)'s business?

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

What is the price predicton of PAHC Stock?

Wall Street analysts forecast PAHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is47.50 USD with a low forecast of 45.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Phibro Animal Health Corp (PAHC)'s revenue for the last quarter?

Phibro Animal Health Corp revenue for the last quarter amounts to 383.54M USD, increased 10.27

What is Phibro Animal Health Corp (PAHC)'s earnings per share (EPS) for the last quarter?

Phibro Animal Health Corp. EPS for the last quarter amounts to 0.59 USD, increased 15.69

How many employees does Phibro Animal Health Corp (PAHC). have?

Phibro Animal Health Corp (PAHC) has 2475 emplpoyees as of May 12 2026.

What is Phibro Animal Health Corp (PAHC) market cap?

Today PAHC has the market capitalization of 1.47B USD.